TNF Inhibition for Alzheimer's Dementia Falls Short Medscape In a small phase 2 study of patients with early Alzheimer's disease (AD), weekly subcutaneous administration of the tumor necrosis factor (TNF) inhibitor etanercept (Enbrel, Amgen) was well tolerated, with a signal of benefit on psychiatric symptoms ... |